These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 37294961)
21. Biology and therapy of mantle cell lymphoma. Williams ME; Densmore JJ Curr Opin Oncol; 2005 Sep; 17(5):425-31. PubMed ID: 16093790 [TBL] [Abstract][Full Text] [Related]
22. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. Yoon DH; Cao J; Chen TY; Izutsu K; Kim SJ; Kwong YL; Lin TY; Thye LS; Xu B; Yang DH; Kim WS J Hematol Oncol; 2020 Mar; 13(1):21. PubMed ID: 32183871 [TBL] [Abstract][Full Text] [Related]
23. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group. Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610 [TBL] [Abstract][Full Text] [Related]
24. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Shah BD; Martin P; Sotomayor EM Cancer Control; 2012 Jul; 19(3):227-35. PubMed ID: 22710898 [TBL] [Abstract][Full Text] [Related]
26. Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. Cohen JB; Zain JM; Kahl BS Am Soc Clin Oncol Educ Book; 2017; 37():512-525. PubMed ID: 28561694 [TBL] [Abstract][Full Text] [Related]
27. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. Zaja F; Federico M; Vitolo U; Zinzani PL Leuk Lymphoma; 2014 May; 55(5):988-98. PubMed ID: 23865835 [TBL] [Abstract][Full Text] [Related]
28. Diagnosis and treatment of mantle cell lymphoma. Hitz F; Bargetzi M; Cogliatti S; Lohri A; Taverna C; Renner C; Mey U Swiss Med Wkly; 2013; 143():w13868. PubMed ID: 24226630 [TBL] [Abstract][Full Text] [Related]
29. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Jain P; Wang M Am J Hematol; 2019 Jun; 94(6):710-725. PubMed ID: 30963600 [TBL] [Abstract][Full Text] [Related]
30. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837 [TBL] [Abstract][Full Text] [Related]
31. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390 [TBL] [Abstract][Full Text] [Related]
32. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498 [TBL] [Abstract][Full Text] [Related]
33. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. Klener P Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500350 [TBL] [Abstract][Full Text] [Related]
34. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299 [TBL] [Abstract][Full Text] [Related]
35. Molecular profiling and management of mantle cell lymphoma. Ruan J Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):30-40. PubMed ID: 31808882 [TBL] [Abstract][Full Text] [Related]
36. Update on mantle cell lymphoma. Maddocks K Blood; 2018 Oct; 132(16):1647-1656. PubMed ID: 30154113 [TBL] [Abstract][Full Text] [Related]
37. Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Mussetti A; Kumar A; Dahi PB; Perales MA; Sauter CS Blood Rev; 2015 May; 29(3):143-52. PubMed ID: 25468719 [TBL] [Abstract][Full Text] [Related]
39. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Williams ME; Connors JM; Dreyling MH; Gascoyne RD; Kahl BS; Leonard JP; Press OW; Wilson WH Leuk Lymphoma; 2011 Jan; 52(1):24-33. PubMed ID: 21133727 [TBL] [Abstract][Full Text] [Related]
40. Mantle cell lymphoma - Current standards of care and future directions. Martin P; Ghione P; Dreyling M Cancer Treat Rev; 2017 Jul; 58():51-60. PubMed ID: 28651117 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]